Association between the p53 polymorphisms and breast cancer risk: Meta-analysis based on case-control study

Breast Cancer Research and Treatment

Volumn 130, Issue 2, 2011, Pages 517-529

  He, Xiao Feng ^a   Su, Jiao ^a   Zhang, Ying ^b   Huang, Xian ^c   Liu, Yi ^d   Ding, Da Peng ^d   Wang, Wei ^d,e   Arparkorn, K ^f  

^a CHANGZHI MEDICAL COLLEGE   (China)

^b JINAN UNIVERSITY   (China)

^c Center for Chronic Disease Control   (China)

^d SOUTHERN MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF FUKUI   (Japan)

^f MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Breast cancer; Meta analysis; Polymorphism; TP53

Indexed keywords

PROTEIN P53;

ARTICLE; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CODON; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; INDIAN; INHERITANCE; PRIORITY JOURNAL; RECESSIVE INHERITANCE; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; CODON; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOMOZYGOTE; HUMANS; INTRONS; POLYMORPHISM, GENETIC; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 82955233543     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1583-2     Document Type: Article

References (74)

1. Berns EM, van Staveren IL, Look MP, Smid M, Klijn JGM, Foekens JA (1998) Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer. Br J Cancer 77:1130-1136 (Pubitemid 28116285)
2. Parkin DM, Bray F, Ferlay J et al (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153-156 (Pubitemid 32911406)
3. Veronesi U, Boyle P, Golsdhirsch A, Orecchia R, Viale G (2005) Breast cancer. Lancet 365:1727-1741 (Pubitemid 40719108)
4. Yager JD, Davidson NE (2006) Mechanism of disease: estrogen carcinogenesis in breast cancer. N Engl J Med 354:270-282
5. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70 (Pubitemid 30046295)
6. Dumitrescu RG, Cotarla I (2005) Understanding breast cancer risk\-where do we stand in 2005? J Cell Mol Med 9:208-221
7. Hollstein M, Sidransky D, Vogelstein B et al (1991) p53 muta-tions in human cancers. Science 253:49-53
8. Oren M (2003) Decision making by p53: life, death and cancer. Cell Death 10:431-442 (Pubitemid 36626355)
9. Denehower LA (2005) p53 guardian and suppressor oflongevity? Exp Gerontol 40:7-9
10. Dumont P, Leu JI, Della Pietra ACIII et al (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357-365 (Pubitemid 36278852)
11. Zhang Z, Wang M, Wu D, Wang M, Tong N, Tian Y, Zhang Z (2010) P53 codon 72 polymorphism contributes to breast cancer risk: a meta-analysis based on 39 case-control studies. Breast Cancer Res Treat 120(2):509-517
12. Hu Z, Li X, Yuan R, Ring BZ, Su L (2010) Three common TP53 polymorphisms in susceptibility to breast cancer, evidence from meta-analysis. Breast Cancer Res Treat 120(3):705-714
13. Ma Y, Yang J, Liu Z, Zhang P, Yang Z, Wang Y, Qin H (2011) No significant association between the TP53 codon 72 polymorphism and breast cancer risk: a meta-analysis of 21 studies involving 24,063 subjects. Breast Cancer Res Treat 125(1):201-205
14. Francisco G, Menezes PR, Eluf-Neto J, Chammas R (2010) Arg72Pro TP53 polymorphism and cancer susceptibility: a comprehensive meta-analysis of 302 case-control studies. Int J Cancer. doi:10.1002/ijc.25710
15. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S (1993) Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 14:1085-1089 (Pubitemid 23193532)
16. Sjalander A, Birgander R, Hallmans G, Cajander S, Lenner P, Athlin L, Beckman G, Beckman L (1996) p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 17:1313-1316
17. Weston A, Pan CF, Ksieski HB, Wallenstein S, Berkowitz GS, Tartter PI, Bleiweiss IJ, Brower ST, Senie RT, Wolff MS (1997) p53 haplotype determination in breast cancer. Cancer Epidemiol Biomarkers Prev 6:105-112 (Pubitemid 27069203)
18. Helland A, Langerod A, Johnsen H, Olsen AO, Skovlund E, Borresen-Dale AL (1998) p53 polymorphism and risk ofcervical cancer. Nature 396:530-531
19. Wang-Gohrke S, Rebbeck TR, Besenfelder W et al (1998) p53 germline polymorphisms are associated with an increased risk for breast cancer in German women. Anticancer Res 18:2095-2099 (Pubitemid 28344879)
20. Khaliq S, Hameed A, Khaliq T et al (2000) P53 mutations, polymorphisms, and haplotypes in Pakistani ethnic groups and breast cancer patients. Genet Test 4:23-29 (Pubitemid 30217737)
21. Papadakis EN, Dokianakis DN, Spandidos DA (2000) p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun 3:389-392
22. Li T, Lu ZM, Guo M, Wu QJ, Chen KN, Xing HP, Mei Q, Ke Y (2002) p53 codon 72 polymorphism (C/G) and the risk of human papillomavirus-associated carcinomas in China. Cancer 95: 2571-2576 (Pubitemid 35424044)
23. Wang-Gohrke S, Becher H, Kreienberg R, Runnebaum IB, Chang-Claude J (2003) Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years. Pharmacogenetics 12:269-272
24. Buyru N, Tigli H, Dalay N (2003) P53 codon 72 polymorphism in breast cancer. Oncol Rep 10:711-714
25. Mabrouk I, Baccouche S, El-Abed R, Mokdad-Gargouri R, Mosbah A, Sǎ̈d S, Daoud J, Frikha M, Jlidi R, Gargouri A (2003) No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann N Y Acad Sci 1010:764-770 (Pubitemid 38265078)
26. Huang XE, Hamajima N, Katsuda N, Matsuo K, Hirose K, Mizutani M, Iwata H, Miura S, Xiang J, Tokudome S, Tajima K (2003) Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer 10:307-311
27. Katiyar S, Thelma BK, Murthy NS, Hedau S, Jain N, Gop-alkrishna V, Husain SA, Das BC (2003) Polymorphism of the p53 codon 72 Arg/Pro and the risk of HPV type 16/18-associated cervical and oral cancer in India. Mol Cell Biochem 252:117-124 (Pubitemid 37220740)
28. Suspitsin EN, Buslov KG, Grigoriev MY, Ishutkina JG, Ulibina JM, Gorodinskaya VM, Pozharisski KM, Berstein LM, Hanson KP, Togo AV, Imyanitov EN (2003) Evidence against involve-ment of P53 polymorphism in breast cancer predisposition. Int J Cancer 103:431-433 (Pubitemid 36076439)
29. Menzel HJ, Sarmanova J, Soucek P, Berberich R, Grünewald K, Haun M, Kraft HG (2004) Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations. Br J Cancer 90:1989-1994 (Pubitemid 38746342)
30. Noma C, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S (2004) Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. Cancer Lett 210:197-203 (Pubitemid 38748690)
31. Mahasneh AA, Abdel-Hafiz SS (2004) Polymorphism of p53 gene in Jordanian population and possible associations with breast cancer and lung adenocarcinoma. Saudi Med J 25:1568-1573 (Pubitemid 39646625)
32. Tommiska J, Eerola H, Heinonen M, Salonen L, Kaare M, Tallila J, Ristimäki A, von Smitten K, Aittomäki K, Heikkilä P, Blomqvist C, Nevanlinna H (2005) Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 11:5098-5103 (Pubitemid 41003693)
33. Kalemi TG, Lambropoulos AF, Gueorguiev M, Chrisafi S, Pap-azisis KT, Kotsis A (2005) The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymor-phisms with breast cancer in Northern Greece. Cancer Lett 222:57-65 (Pubitemid 40544847)
34. Siddique MM, Balram C, Fiszer-Maliszewska L, Aggarwal A, Tan A, Tan P, Soo KC, Sabapathy K (2005) Evidence for selective expression of the p53 codon 72 polymorphs: implica-tions in cancer development. Cancer Epidemiol Biomarkers Prev 14:2245-2252 (Pubitemid 41603274)
35. Ohayon T, Gershoni-Baruch R, Papa MZ, Distelman Menachem T, Eisenberg Barzilai S, Friedman E (2005) The R72P P53 mutation is associated with familial breast cancer in Jewish women. Br J Cancer 92:1144-1148 (Pubitemid 40546682)
36. Damin AP, Frazzon AP, Damin DC, Roehe A, Hermes V, Zettler C, Alexandre CO (2006) Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk. Cancer Detect Prev 30:523-529 (Pubitemid 44828290)
37. Ma H, Hu Z, Zhai X, Wang S, Wang X, Qin J, Chen W, Jin G, Liu J, Gao J, Wang X, Wei Q, Shen H (2006) Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population. Carcinogenesis 27:766-771
38. Baynes C, Healey CS, Pooley KA, Scollen S, Luben RN, Thompson DJ, Pharoah PD, Easton DF, Ponder BA, Dunning AM (2007) SEARCH breast cancer study: common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. Breast Cancer Res 9(2):R27
39. Gochhait S, Bukhari SI, Bairwa N, Vadhera S, Darvishi K, Raish M, Gupta P, Husain SA, Bamezai RN (2007) Implication of BRCA2-26G>A 5' untranslated region polymorphism in sus-ceptibility to sporadic breast cancer and its modulation by p53 codon 72 Arg>Pro polymorphism. Breast Cancer Res 9:R71
40. Khadang B, Fattahi MJ, Talei A, Dehaghani AS, Ghaderi A (2007) Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. Cancer Genet Cytogenet 173:38-42 (Pubitemid 46187296)
41. Schmidt MK, Reincke S, Broeks A, Braaf LM, Hogervorst FB, Tollenaar RA, Johnson N, Fletcher O, Peto J, Tommiska J, Blomq-vist C, Nevanlinna HA, Healey CS, Dunning AM, Pharoah PD, Easton DF, Dörk T, Van't Veer LJ (2007) Breast cancer association consortium: do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. Cancer Res 67:9584-9590 (Pubitemid 47535950)
42. Sprague BL, Trentham-Dietz A, Garcia-Closas M, Newcomb PA, Titus-Ernstoff L, Hampton JM, Chanock SJ, Haines JL, Egan KM (2007) Genetic variation in TP53 and risk of breast cancer in a population-based case control study. Carcinogenesis 28:1680-1686 (Pubitemid 47289028)
43. Zhang W, Jin MJ, Chen K (2007) Association of p53 polymor-phisms and its haplotypes with susceptibility of breast cancer. Zhejiang Da Xue Xue Bao Yi Xue Ban 36:561-566
44. Rajkumar T, Samson M, Rama R, Sridevi V, Mahji U, Swami-nathan R, Nancy N (2008) TGFb1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFb1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy. Breast Cancer Res Treat 112:81-87
45. Cox DG, Deer D, Guo Q, Tworoger SS, Hankinson SE, Hunter DJ, De Vivo I (2007) The p53 Arg72Pro and MDM2-309 poly-morphisms and risk ofbreast cancer in the nurses' health studies. Cancer Causes Control 18:621-625 (Pubitemid 46883679)
46. Gaudet MM, Gammon MD, Bensen JT, Sagiv SK, Shantakumar S, Teitelbaum SL, Eng SM, Neugut AI, Santella RM (2008) Genetic variation of TP53, polycyclic aromatic hydrocarbonre-lated exposures, and breast cancer risk among women on Long Island, New York. Breast Cancer Res Treat 108:93-99 (Pubitemid 351623233)
47. Garcia-Closas M, Kristensen V, Langerod A, Qi Y, Yeager M, Burdett L, Welch R, Lissowska J, Peplonska B, Brinton L, Gerhard DS, Gram IT, Perou CM, Borresen-Dale AL, Chanock S (2007) Common genetic variation in TP53 and its flanking genes, WDR79 and ATP1B2, and susceptibility to breast cancer. Int J Cancer 121:2532-2538 (Pubitemid 350022425)
48. Johnson N, Fletcher O, Palles C, Rudd M, Webb E, Sellick G, dos Santos Silva I, Mc Cormack V, Gibson L, Fraser A, Leonard A, Gilham C, Tavtigian SV, Ashworth A, Houlston R, Peto J (2007) Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. Hum Mol Genet 16: 1051-1057 (Pubitemid 47062726)
49. Franeková M, Zúbor P, Stanclová A, Dussan CA, Bohusová T, Galo S, Dobrota D, Kajo K, Péc M, Racay P (2007) Association of p53 polymorphisms with breast cancer: a case-control study in Slovak population. Neoplasma 54:155-161
50. Pharoah PD, Tyrer J, Dunning AM, Easton DF, Ponder BA, SEARCH Investigators (2007) Association between common variation in 120 candidate genes and breast cancer risk. PLoS Genet 3:e42
51. Samson M, Swaminathan R, Rama R, Sridevi V, Nancy KN, Rajkumar T (2007) Role of GSTM1 (Null/Present), GSTP1 (Ile105Val) and P53 (Arg72Pro) genetic polymorphisms and the risk of breast cancer: a case control study from South India. Asian Pac J Cancer Prev 8:253-257
52. Akkiprik M, Sonmez O, Gulluoglu BM, Caglar HB, Kaya H, Demirkalem P, Abacioglu U, Sengoz M, Sav A, Ozer A (2009) Analysis of p53 gene polymorphisms and protein over-expression in patients with breast cancer. Pathol Oncol Res 15:359-368
53. Singh V, Rastogi N, Mathur N, Singh K, Singh MP (2008) Association of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian women. Ann Epidemiol 18:48-57 (Pubitemid 350184342)
54. Lum SS, Chua HW, Li H, Li WF, Rao N, Wei J, Shao Z, Sabapathy K (2008) MDM2 SNP309 G allele increases risk but the Tallele is associated with earlier onset age of sporadic breast cancers in the Chinese population. Carcinogenesis 29:754-761 (Pubitemid 351494162)
55. Cavallone L, Arcand SL, Maugard C, Ghadirian P, Mes-Masson AM, Provencher D, Tonin PN (2008) Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent. BMC Cancer 8:96
56. Costa S, Pinto D, Pereira D, Rodrigues H, Cameselle-Teijeiro J, Medeiros R, Schmitt F (2008) Importance of TP53 codon 72 and intron 3 duplication 16 bp polymorphisms in prediction of sus-ceptibility on breast cancer. BMC Cancer 8:32
57. De Vecchi G, Verderio P, Pizzamiglio S, Manoukian S, Bernard L, Pensotti V, Volorio S, Ravagnani F, Radice P, Peterlongo P (2008) The p53 Arg72Pro and Ins16 bp polymorphisms and their haplotypes are not associated with breast cancer risk in BRCA-mutation negative familial cases. Cancer Detect Prev 32:140-143
58. Nordgard SH, Alnaes GI, Hihn B et al (2008) Pathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral m RNA expression and survival. Int J Cancer 123: 577-585 (Pubitemid 351898415)
59. Henrirquez-Hernandez LA, Murias-Rosales A, Herna'ndez GA, Cabrera DLA, Di'az-Chico BN, Mori DSM, Ferna'ndez PL (2009) Gene polymorphisms in TYMS, MTHFR, p53 and MDR1 as risk factors for breast cancer: a case-control study. Oncol Rep 22: 1425-1433
60. Kazemi M, Salehi Z, Chakosari RJ (2009) TP53 codon 72 polymorphism and breast cancer in northern Iran. Oncol Res 18(1):25-30
61. Denisov EV, Cherdyntseva NV, Litvyakov NV, Slonimskaya EM (2009) TP53 mutations and Arg72Pro polymorphism in breast cancers. Cancer Genet Cytogenet 192:93-95
62. Aoki MN, da Silva AHAC, Amarante MK, do Val Carneiro JL, Fungaro MH, Watanabe MA (2009) CCR5 and p53 codon 72 gene polymorphisms: implications in breast cancer development. Int J Mol Med 23:429-435
63. Song F, Zheng H, Liu B, Wei S, Dai H, Zhang L, Calin GA, Hao X, Wei Q, Zhang W, Chen K (2009) An mi R-502-binding site single-nucleotide polymorphism in the 3'-untranslated region of the SET8 gene is associated with early age ofbreast cancer onset. Clin Cancer Res 15(19):6292-6300
64. Lǎng A, Palmebäck Wegman P, Wingren S (2009) The signifi-cance of MDM2 SNP309 and p53 Arg72Pro in young women with breast cancer. Oncol Rep 22:575-579
65. Hrstka R, Beranek M, Klocova K, Nenutil R, Vojtesek B (2009) Intronic polymorphisms in TP53 indicate lymph node metastasis in breast cancer. Oncol Rep 22:1205-1211
66. Kara N, Karakus N, Ulusoy AN, Ozaslan C, Gungor B, Bagci H (2010) P53 codon 72 and HER2 codon 655 polymorphisms in Turkish breast cancer patients. DNA Cell Biol 29:7
67. Ebner F, Schremmer-Danninger E, Rehbock J (2010) The role of TP53 and p21 gene polymorphisms in breast cancer biology in a well specified and characterized German cohort. J Cancer Res Clin Oncol 136:1369-1375
68. Bisof V, Salihović MP, Narancić NS, Skarić- Jurić T, Jakić-Razumović J, Janićijević B, Turek S, Rudan P (2010) TP53 gene polymorphisms and breast cancer in Croatian women: a pilot study. Eur J Gynaecol Oncol 31(5):539-544
69. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748
70. Der Simonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188 (Pubitemid 17189972)
71. Thompson SG, Higgins JPT (2002) How meta-regression analy-ses be undertaken and ihterpreted? Statist Med 21:1559-1573 (Pubitemid 34746063)
72. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4): 1088-1101
73. Egger M, Smith DG, Schneider M (1997) Minder C Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634 (Pubitemid 27387172)
74. Buyru N, Altinisik J, Demokan S, Dalay N (2007) p53 genotypes 153 and haplotypes associated with risk ofbreast cancer. Cancer Detect Prev 31:207-213 (Pubitemid 47248151)